Parallel Advisors’s Ginkgo Bioworks DNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.09K Hold
312
﹤0.01% 3395
2026
Q1
$1.91K Sell
312
-126
-29% -$1.05K ﹤0.01% 3390
2025
Q4
$3.64K Hold
438
﹤0.01% 2946
2025
Q3
$6.39K Sell
438
-36
-8% -$431 ﹤0.01% 2687
2025
Q2
$5.33K Buy
474
+248
+110% +$1.92K ﹤0.01% 2721
2025
Q1
$1.29K Buy
226
+56
+33% +$571 ﹤0.01% 3070
2024
Q4
$1.67K Hold
170
﹤0.01% 3017
2024
Q3
$1.39K Sell
170
-23
-12% -$230 ﹤0.01% 2969
2024
Q2
$2.58K Sell
193
-96
-33% -$2.86K ﹤0.01% 2730
2024
Q1
$13.4K Buy
289
+10
+4% +$518 ﹤0.01% 2174
2023
Q4
$18.8K Sell
279
-33
-11% -$2.02K ﹤0.01% 1987
2023
Q3
$22.6K Buy
312
+3
+1% +$240 ﹤0.01% 1778
2023
Q2
$23K Buy
309
+110
+55% +$6.51K ﹤0.01% 1783
2023
Q1
$10.6K Sell
199
-62
-24% -$3.93K ﹤0.01% 2103
2022
Q4
$17.6K Buy
261
+59
+29% +$5.43K ﹤0.01% 1766
2022
Q3
$25K Buy
202
+32
+19% +$3.81K ﹤0.01% 1579
2022
Q2
$16K Buy
+170
New +$20.7K ﹤0.01% 1758
2021
Q4
Sell
-63
Closed -$29K 3133
2021
Q3
$29K Buy
+63
New +$30.7K ﹤0.01% 1545

Other funds holding DNA

Parallel Advisors's DNA Position: Q2 2026 in Review

Parallel Advisors held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 312 shares worth $3.09K. The position accounts for ﹤0.01% of the portfolio, ranked #3395.

Parallel Advisors first reported a position in DNA in Q3 2021 and has held it in 18 quarters since. The position peaked at $29K in Q3 2021. 183 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Parallel Advisors held 312 shares of Ginkgo Bioworks worth $3.09K as of Q2 2026.
  • Parallel Advisors left its Ginkgo Bioworks share count unchanged in Q2 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3395 holding.
  • Parallel Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and has held it in 18 quarters since.
  • Parallel Advisors's Ginkgo Bioworks position peaked at $29K in Q3 2021.
  • 183 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.